FDA has approved the Valiant Navion thoracic stent graft system for the minimally invasive repair of descending thoracic aorta lesions from Medtronic plc. The system from the Dublin-based company is a new iteration of the prior Valiant Captivia thoracic stent graft system, which has been used on more than 100,000 patients globally.